249 related articles for article (PubMed ID: 17007969)
21. Recombinant Sindbis virus vectors designed to express protective antigen of Bacillus anthracis protect animals from anthrax and display synergy with ciprofloxacin.
Thomas JM; Moen ST; Gnade BT; Vargas-Inchaustegui DA; Foltz SM; Suarez G; Heidner HW; König R; Chopra AK; Peterson JW
Clin Vaccine Immunol; 2009 Nov; 16(11):1696-9. PubMed ID: 19759250
[TBL] [Abstract][Full Text] [Related]
22. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin.
Gaur R; Gupta PK; Banerjea AC; Singh Y
Vaccine; 2002 Jun; 20(21-22):2836-9. PubMed ID: 12034111
[TBL] [Abstract][Full Text] [Related]
23. BA3338, a surface layer homology domain possessing protein augments immune response and protection efficacy of protective antigen against Bacillus anthracis in mouse model.
Kumar M; Puranik N; Varshney A; Tripathi N; Pal V; Goel AK
J Appl Microbiol; 2020 Aug; 129(2):443-452. PubMed ID: 32118336
[TBL] [Abstract][Full Text] [Related]
24. Mucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodies.
Ramirez K; Ditamo Y; Galen JE; Baillie LW; Pasetti MF
Vaccine; 2010 Aug; 28(37):6065-75. PubMed ID: 20619377
[TBL] [Abstract][Full Text] [Related]
25. A plant-produced protective antigen vaccine confers protection in rabbits against a lethal aerosolized challenge with Bacillus anthracis Ames spores.
Chichester JA; Manceva SD; Rhee A; Coffin MV; Musiychuk K; Mett V; Shamloul M; Norikane J; Streatfield SJ; Yusibov V
Hum Vaccin Immunother; 2013 Mar; 9(3):544-52. PubMed ID: 23324615
[TBL] [Abstract][Full Text] [Related]
26. Efficacious, nontoxigenic Bacillus anthracis spore vaccines based on strains expressing mutant variants of lethal toxin components.
Mendelson I; Gat O; Aloni-Grinstein R; Altboum Z; Inbar I; Kronman C; Bar-Haim E; Cohen S; Velan B; Shafferman A
Vaccine; 2005 Dec; 23(48-49):5688-97. PubMed ID: 16039760
[TBL] [Abstract][Full Text] [Related]
27. N-fragment of edema factor as a candidate antigen for immunization against anthrax.
Zeng M; Xu Q; Hesek ED; Pichichero ME
Vaccine; 2006 Jan; 24(5):662-70. PubMed ID: 16157430
[TBL] [Abstract][Full Text] [Related]
28. A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes.
Chitlaru T; Israeli M; Rotem S; Elia U; Bar-Haim E; Ehrlich S; Cohen O; Shafferman A
Vaccine; 2017 Oct; 35(44):6030-6040. PubMed ID: 28342664
[TBL] [Abstract][Full Text] [Related]
29. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice.
Flick-Smith HC; Eyles JE; Hebdon R; Waters EL; Beedham RJ; Stagg TJ; Miller J; Alpar HO; Baillie LW; Williamson ED
Infect Immun; 2002 Apr; 70(4):2022-8. PubMed ID: 11895967
[TBL] [Abstract][Full Text] [Related]
30. Anthrax spores make an essential contribution to vaccine efficacy.
Brossier F; Levy M; Mock M
Infect Immun; 2002 Feb; 70(2):661-4. PubMed ID: 11796596
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.
Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM
FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653
[TBL] [Abstract][Full Text] [Related]
32. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.
Park YS; Lee JH; Hung CF; Wu TC; Kim TW
Infect Immun; 2008 May; 76(5):1952-9. PubMed ID: 18285494
[TBL] [Abstract][Full Text] [Related]
34. Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen.
Cybulski RJ; Sanz P; McDaniel D; Darnell S; Bull RL; O'Brien AD
Vaccine; 2008 Sep; 26(38):4927-39. PubMed ID: 18657585
[TBL] [Abstract][Full Text] [Related]
35. Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen.
Brahmbhatt TN; Darnell SC; Carvalho HM; Sanz P; Kang TJ; Bull RL; Rasmussen SB; Cross AS; O'Brien AD
Infect Immun; 2007 Nov; 75(11):5240-7. PubMed ID: 17785478
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and immunogenicity of single-dose AdVAV intranasal anthrax vaccine compared to anthrax vaccine absorbed in an aerosolized spore rabbit challenge model.
Krishnan V; Andersen BH; Shoemaker C; Sivko GS; Tordoff KP; Stark GV; Zhang J; Feng T; Duchars M; Roberts MS
Clin Vaccine Immunol; 2015 Apr; 22(4):430-9. PubMed ID: 25673303
[TBL] [Abstract][Full Text] [Related]
37. Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.
Parreiras PM; Sirota LA; Wagner LD; Menzies SL; Arciniega JL
Vaccine; 2009 Jul; 27(33):4537-42. PubMed ID: 19501205
[TBL] [Abstract][Full Text] [Related]
38. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.
Suryanarayana N; Verma M; Thavachelvam K; Saxena N; Mankere B; Tuteja U; Hmuaka V
Appl Microbiol Biotechnol; 2016 Oct; 100(19):8439-51. PubMed ID: 27364624
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the adaptive immune response of donors receiving live anthrax vaccine.
Firstova VV; Shakhova AS; Riabko AK; Silkina MV; Zeninskaya NA; Romanenko YO; Marin MA; Rogozin MM; Kartseva AS; Dyatlov IA; Shemyakin IG
PLoS One; 2021; 16(12):e0260202. PubMed ID: 34928976
[TBL] [Abstract][Full Text] [Related]
40. Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.
Dumas EK; Gross T; Larabee J; Pate L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Collins LC; Spooner CE; Chen H; Ballard J; James JA; Farris AD
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
